MML Investors Services
CYTK icon

MML Investors Services’s Cytokinetics CYTK Stock Holding History

MML Investors Services’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$440K Buy
5,171
+1,524
+42% +$109K ﹤0.01% 2558
2026
Q1 		$240K Sell
3,647
-1,195
-25% -$75.9K ﹤0.01% 2708
2025
Q4 		$308K Buy
+4,842
New +$301K ﹤0.01% 2605

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MML Investors Services's CYTK Position: Q2 2026 in Review

MML Investors Services increased its Cytokinetics (CYTK) stake by 42% in Q2 2026, buying an estimated $109K and bringing the position to 5,171 shares worth $440K. The position accounts for ﹤0.01% of the portfolio, ranked #2558.

MML Investors Services first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • MML Investors Services held 5,171 shares of Cytokinetics worth $440K as of Q2 2026.
  • MML Investors Services bought 1,524 Cytokinetics shares in Q2 2026, an estimated $109K.
  • Cytokinetics made up ﹤0.01% of MML Investors Services's portfolio in Q2 2026, its #2558 holding.
  • MML Investors Services first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.